Prescription Drug Affordability Act: House Bill 154 would create a five-member prescription drug affordability board, the purpose of which is to take action to protect state residents and other stakeholders from the high cost of prescription drugs, Board members would be appointed for their expertise in clinical medicine or health economics and would not be employees of or consultants to pharmaceutical companies or their trade associations. The prescription drug affordability board would consider drugs having a high acquisition cost, specified in the bill, whether they be brand name or generic, as well as those whose cost had rapidly increased and any others deemed to create affordability challenges. The board would look at the manufacturer’s price concessions or rebates, the price of therapeutic alternatives and the overall impact of a drug’s pricing on patient access to the medication, the cost of the medication in other jurisdictions, and the financial impact of the pricing on health, medical and social service costs. If the board determined a given medication to pose an affordability challenge, it would establish an upper payment limit that would apply to all purchases by patients, whether by mail or in person.